Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Up 107.2% in September

Key Points

• Short interest in Swedish Orphan Biovitrum surged by 107.2% in September, climbing to a total of 447,500 shares compared to 216,000 shares at the end of August.
• The stock's current price is $30.05, with a market cap of $10.70 billion and a P/E ratio of 25.25.
• In its last quarterly earnings report, Swedish Orphan Biovitrum outperformed analysts' expectations, reporting $0.24 EPS against the consensus estimate of $0.18.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totaling 447,500 shares, an increase of 107.2% from the August 31st total of 216,000 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 4,475.0 days. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 4,475.0 days.

Swedish Orphan Biovitrum Price Performance

Shares of BIOVF stock remained flat at $30.05 during trading hours on Friday. The stock had a trading volume of 21 shares, compared to its average volume of 7. The stock's 50-day moving average price is $29.77 and its 200-day moving average price is $29.47. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.66 and a current ratio of 1.00. Swedish Orphan Biovitrum has a 12-month low of $25.80 and a 12-month high of $32.01. The stock has a market cap of $10.70 billion, a P/E ratio of 25.25 and a beta of 0.49.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. Swedish Orphan Biovitrum had a return on equity of 11.67% and a net margin of 16.05%.The company had revenue of $649.61 million for the quarter, compared to analysts' expectations of $644.68 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.